

Supplementary Table: Free Testosterone Levels at each visit by treatment group and age.

			Free Testosterone pmoles/L. mean (S.D.)									
	Treatment Group	N	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10
<b>Old</b>	1. GnRH Agonist, T-gel	15	261.0 <sup>^</sup> (67.2)	241.4 (65.5)	472.2* (203.5)	373.0 (120.0)	379.4 (193.5)	419.6 (278.1)	482.8 (333.8)	581.6 (584.9)	347.6 (155.2)	262.2 <sup>#</sup> (129.1)
	2. GnRH Agonist, T-gel, Arimidex	17	278.8 <sup>^</sup> (79.8)	278.1 (70.8)	493.2* (133.6)	372.7* (103.1)	513.8 (260.5)	391.7* (169.2)	407.7 (160.9)	424.0 (259.8)	390.1 (147.1)	293.1 <sup>^</sup> (131.2)
	3. GnRH Agonist, Placebo gel	15	217.1 <sup>^</sup> (44.6)	224.9 (60.4)	414.5 <sup>^</sup> (273.3)	225.3* (156.6)	79.4 (102.7)	29.7* (34.0)	44.8 (76.5)	34.0 (76.2)	10.2 (18.2)	235.4 <sup>#</sup> (84.4)
	4. Placebo	15	235.2* (64.3)	246.4 (80.9)	219.9* (72.7)	252.4 (76.0)	234.3* (86.7)	243.7 (78.6)	230.7 (71.2)	222.8 (69.3)	233.9 (63.6)	245.5 <sup>+</sup> (71.4)
<b>Young</b>	1. GnRH Agonist, T-gel	8	344.0* (86.1)	411.0 (125.8)	882.9* (179.9)	608.4 (109.3)	493.0 (220.3)	505.5* (318.2)	577.4 (232.9)	412.6 (125.1)	541.9 (310.2)	546.7 <sup>+</sup> (228.1)
	2. GnRH Agonist, T-gel, Arimidex	5	332.1* (42.8)	342.8 (96.2)	882.8* (302.3)	613.1 (301.1)	435.2 (404.9)	363.9 (160.4)	322.6 (199.5)	325.6 (205.5)	366.7 (104.3)	672.8* (268.5)
	3. GnRH Agonist, Placebo gel	8	386.0* (101.8)	377.9 (85.7)	641.4 (196.7)	220.8 (115.0)	66.6 (45.3)	15.6* (9.7)	10.3* (8.2)	10.9 (12.0)	6.6 (6.0)	478.8 <sup>^</sup> (188.9)
	4. Placebo	5	364.1* (81.4)	361.7 (97.4)	378.5 (106.0)	404.6 (168.8)	375.3 (78.9)	372.1 (132.2)	403.6 (97.3)	331.1 (97.4)	561.3 (329.1)	369.2* (165.3)

\* Batched sample missing for 1 subject; <sup>^</sup> Batched sample missing for 2 subjects; <sup>+</sup> Batched sample missing for 4 subjects; <sup>#</sup> Batched sample missing for 5 subjects. Non-batched samples were also obtained for Visit 1 screening hormone and Visit 10 safety check.

Supplementary Table: Estradiol Levels at each visit by treatment group and age.

			Estradiol pg/mL mean (S.D.)									
	Treatment Group	N	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10
<b>Old</b>	1. GnRH Agonist, T-gel	15	17.2 <sup>^</sup> (4.2)	17.1 (5.3)	26.2* (10.9)	19.4 (5.5)	19.6 (5.1)	19.7 (7.6)	22.3 (8.4)	20.7 (5.5)	19.1 (6.4)	17.9 <sup>+</sup> (7.2)
	2. GnRH Agonist, T-gel, Arimidex	17	18.2 <sup>§</sup> (4.6)	20.2 (4.4)	33.4* (15.7)	15.9* (6.2)	7.6 (3.0)	7.4* (2.8)	7.5 (2.4)	7.7 (3.0)	8.6 (3.7)	20.5 <sup>^</sup> (6.7)
	3. GnRH Agonist, Placebo gel	15	18.0 <sup>^</sup> (5.1)	17.8 (4.7)	26.1 <sup>^</sup> (9.5)	17.0* (5.6)	11.6 (4.8)	9.9* (3.7)	12.5 (7.1)	11.1 (6.9)	10.6 (3.2)	17.9 <sup>#</sup> (7.1)
	4. Placebo	15	18.7* (5.8)	17.6 (5.3)	16.0* (3.7)	16.0 (4.4)	16.7* (5.5)	16.4 (4.3)	18.9 (5.4)	17.4 (4.7)	17.5 (4.0)	15.7 <sup>+</sup> (4.7)
<b>Young</b>	1. GnRH Agonist, T-gel	8	22.8* (4.2)	24.0 (6.2)	40.5* (13.8)	29.7 (8.0)	25.6 (6.8)	24.2* (6.6)	23.4 (7.1)	22.1 (5.5)	24.8 (7.8)	27.8 <sup>+</sup> (8.1)
	2. GnRH Agonist, T-gel, Arimidex	5	20.7* (6.2)	21.1 (4.8)	33.0* (11.2)	22.4 (8.6)	13.6 (5.7)	10.2 (2.3)	14.0 (5.0)	12.8 (1.6)	10.8 (2.4)	28.4* (7.1)
	3. GnRH Agonist, Placebo gel	8	26.1* (9.3)	26.6 (8.5)	35.9 (15.0)	24.3 (9.4)	15.6 (6.0)	15.6* (2.9)	16.0* (3.7)	15.5 (3.2)	15.8 (5.4)	33.0 <sup>^</sup> (9.6)
	4. Placebo	5	17.6* (3.4)	19.5 (4.6)	18.8 (3.4)	20.0 (4.8)	19.9 (4.8)	17.0 (5.0)	20.7 (2.8)	19.1 (3.7)	22.3 (4.7)	18.1* (4.1)

\* Batched sample missing for 1 subject; <sup>^</sup> Batched sample missing for 2 subjects; <sup>§</sup> Batched sample missing for 3 subjects; <sup>+</sup> Batched sample missing for 4 subjects; <sup>#</sup> Batched sample missing for 5 subjects. Non-batched samples were also obtained for Visit 1 screening hormone and Visit 10 safety check.